Biogen Inc. $BIIB Shares Sold by Jefferies Financial Group Inc.

Jefferies Financial Group Inc. lowered its stake in Biogen Inc. (NASDAQ:BIIB) by 17.6% during the third quarter, Holdings Channel.com reports. The institutional investor owned 30,600 shares of the biotechnology company’s stock after selling 6,517 shares during the period. Jefferies Financial Group Inc.’s holdings in Biogen were worth $4,286,000 at the end of the most recent reporting period.

Other large investors have also recently bought and sold shares of the company. Elevation Point Wealth Partners LLC purchased a new position in Biogen during the second quarter worth $25,000. Accredited Wealth Management LLC lifted its position in shares of Biogen by 1,233.3% in the third quarter. Accredited Wealth Management LLC now owns 200 shares of the biotechnology company’s stock valued at $28,000 after acquiring an additional 185 shares in the last quarter. Rothschild Investment LLC lifted its position in shares of Biogen by 64.7% in the second quarter. Rothschild Investment LLC now owns 224 shares of the biotechnology company’s stock valued at $28,000 after acquiring an additional 88 shares in the last quarter. True Wealth Design LLC boosted its stake in shares of Biogen by 62.9% during the third quarter. True Wealth Design LLC now owns 233 shares of the biotechnology company’s stock valued at $33,000 after acquiring an additional 90 shares during the last quarter. Finally, WFA of San Diego LLC acquired a new stake in shares of Biogen during the second quarter valued at $32,000. Institutional investors and hedge funds own 87.93% of the company’s stock.

Insider Buying and Selling at Biogen

In related news, insider Priya Singhal sold 2,660 shares of the firm’s stock in a transaction that occurred on Monday, February 9th. The shares were sold at an average price of $199.83, for a total value of $531,547.80. Following the sale, the insider directly owned 8,043 shares of the company’s stock, valued at approximately $1,607,232.69. This trade represents a 24.85% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 0.18% of the stock is currently owned by insiders.

Biogen Stock Performance

Biogen stock opened at $188.24 on Tuesday. The stock has a fifty day moving average price of $183.31 and a 200 day moving average price of $165.80. Biogen Inc. has a 52 week low of $110.04 and a 52 week high of $202.41. The firm has a market capitalization of $27.63 billion, a P/E ratio of 21.37, a PEG ratio of 1.47 and a beta of 0.15. The company has a current ratio of 2.68, a quick ratio of 2.03 and a debt-to-equity ratio of 0.34.

Biogen (NASDAQ:BIIB) last issued its quarterly earnings results on Friday, February 6th. The biotechnology company reported $1.99 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.61 by $0.38. The firm had revenue of $2.28 billion for the quarter, compared to analyst estimates of $2.21 billion. Biogen had a return on equity of 12.64% and a net margin of 13.07%.The firm’s quarterly revenue was down 7.2% on a year-over-year basis. During the same period last year, the company earned $3.44 EPS. Biogen has set its FY 2026 guidance at 15.250-16.250 EPS. Equities research analysts anticipate that Biogen Inc. will post 15.83 earnings per share for the current year.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on the stock. BMO Capital Markets boosted their target price on shares of Biogen from $165.00 to $196.00 and gave the company a “market perform” rating in a research note on Friday, February 6th. Wells Fargo & Company upped their target price on shares of Biogen from $190.00 to $200.00 and gave the company an “equal weight” rating in a report on Sunday, February 8th. Jefferies Financial Group raised their price target on shares of Biogen from $190.00 to $210.00 and gave the stock a “buy” rating in a research note on Friday, November 28th. The Goldman Sachs Group reiterated a “buy” rating on shares of Biogen in a report on Monday, February 9th. Finally, Morgan Stanley set a $190.00 price objective on shares of Biogen in a research report on Sunday, February 8th. Twelve research analysts have rated the stock with a Buy rating and fifteen have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $205.04.

Biogen Company Profile

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.